2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Leonard G. Gomella, MD, chair of Urology at Thomas Jefferson University Hospital and Director of Clinical Affairs at the Kimmel Cancer Center, discusses the debate surrounding PSA-based screening in prostate cancer in 2013.
Leonard G. Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the debate surrounding PSA-based screening in prostate cancer in 2013.
The PSA screening debate has been beneficial, Gomella says, because it forces oncologists to go back, justify, and dissect the best way to screen patients for prostate cancer. It is recognized that not every patient needs to be screen but the challenge lies in identifying those who do and those who will benefit the most from PSA-based screening.
The combination of screening and understanding prostate cancer treatment must be considered together.